Uso precoz de la eritropoyetina en la prevención de la anemia del prematuro

Background: Anemia is common among very low birth weight newborns and requires frequent blood tranfusions. Erythropoietin was been reported to be useful in the prevention of this anemia. Aim: To asses the benefits of early (before the third week of life) Human recombinant Erythropoietin (r-EPO) admi...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Salvadó G,Antonio, Ramolfo B,Pamela, Escobar M,Marisol, Núñez C,Alejandra, Aguayo T,Inés, Standen H,Jane, Sánchez G,Lina, Cabello M,Angela
Lenguaje:	Spanish / Castilian
Publicado:	Sociedad Médica de Santiago 2000
Materias:	Anemia neonatal Erythropoietin Infant, low birth weight
Acceso en línea:	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872000001200002
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:scielo:S0034-98872000001200002
record_format	dspace
spelling	oai:scielo:S0034-988720000012000022001-02-08Uso precoz de la eritropoyetina en la prevención de la anemia del prematuroSalvadó G,AntonioRamolfo B,PamelaEscobar M,MarisolNúñez C,AlejandraAguayo T,InésStanden H,JaneSánchez G,LinaCabello M,Angela Anemia neonatal Erythropoietin Infant, low birth weight Background: Anemia is common among very low birth weight newborns and requires frequent blood tranfusions. Erythropoietin was been reported to be useful in the prevention of this anemia. Aim: To asses the benefits of early (before the third week of life) Human recombinant Erythropoietin (r-EPO) administration to reduce the requirement of blood tranfusions in very low birth weight newborns. Patients and methods: sixty newborns under 1500g of birthweight were randomly assigned to recive r-EPO (n=29) or placebo (n=31) three times per week, during four weeks. Packed red cell volume and reticulocyte counts were measured weekly. Serum erythropoietin was measured prior to eigth dose. Transfusion requirements were recorded. Results: r-EPO reduced transfusions from 1.41 ± 1.1 to 0.69 ± 1 transfusions/newborns (p<0.001). At the fourth week of treatment, reticulocyte count was 14.8 ± 7 and 6.4 ± 4.9% in the active treatment group and placebo group respectively (p<0.001). Conclusions: r-EPO reduces the requrement of transfusions in low birth weight infants (Rev Méd Chile 2000; 128: 1313-17).info:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.128 n.12 20002000-12-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872000001200002es10.4067/S0034-98872000001200002
institution	Scielo Chile
collection	Scielo Chile
language	Spanish / Castilian
topic	Anemia neonatal Erythropoietin Infant, low birth weight
spellingShingle	Anemia neonatal Erythropoietin Infant, low birth weight Salvadó G,Antonio Ramolfo B,Pamela Escobar M,Marisol Núñez C,Alejandra Aguayo T,Inés Standen H,Jane Sánchez G,Lina Cabello M,Angela Uso precoz de la eritropoyetina en la prevención de la anemia del prematuro
description	Background: Anemia is common among very low birth weight newborns and requires frequent blood tranfusions. Erythropoietin was been reported to be useful in the prevention of this anemia. Aim: To asses the benefits of early (before the third week of life) Human recombinant Erythropoietin (r-EPO) administration to reduce the requirement of blood tranfusions in very low birth weight newborns. Patients and methods: sixty newborns under 1500g of birthweight were randomly assigned to recive r-EPO (n=29) or placebo (n=31) three times per week, during four weeks. Packed red cell volume and reticulocyte counts were measured weekly. Serum erythropoietin was measured prior to eigth dose. Transfusion requirements were recorded. Results: r-EPO reduced transfusions from 1.41 ± 1.1 to 0.69 ± 1 transfusions/newborns (p<0.001). At the fourth week of treatment, reticulocyte count was 14.8 ± 7 and 6.4 ± 4.9% in the active treatment group and placebo group respectively (p<0.001). Conclusions: r-EPO reduces the requrement of transfusions in low birth weight infants (Rev Méd Chile 2000; 128: 1313-17).
author	Salvadó G,Antonio Ramolfo B,Pamela Escobar M,Marisol Núñez C,Alejandra Aguayo T,Inés Standen H,Jane Sánchez G,Lina Cabello M,Angela
author_facet	Salvadó G,Antonio Ramolfo B,Pamela Escobar M,Marisol Núñez C,Alejandra Aguayo T,Inés Standen H,Jane Sánchez G,Lina Cabello M,Angela
author_sort	Salvadó G,Antonio
title	Uso precoz de la eritropoyetina en la prevención de la anemia del prematuro
title_short	Uso precoz de la eritropoyetina en la prevención de la anemia del prematuro
title_full	Uso precoz de la eritropoyetina en la prevención de la anemia del prematuro
title_fullStr	Uso precoz de la eritropoyetina en la prevención de la anemia del prematuro
title_full_unstemmed	Uso precoz de la eritropoyetina en la prevención de la anemia del prematuro
title_sort	uso precoz de la eritropoyetina en la prevención de la anemia del prematuro
publisher	Sociedad Médica de Santiago
publishDate	2000
url	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872000001200002
work_keys_str_mv	AT salvadogantonio usoprecozdelaeritropoyetinaenlaprevenciondelaanemiadelprematuro AT ramolfobpamela usoprecozdelaeritropoyetinaenlaprevenciondelaanemiadelprematuro AT escobarmmarisol usoprecozdelaeritropoyetinaenlaprevenciondelaanemiadelprematuro AT nunezcalejandra usoprecozdelaeritropoyetinaenlaprevenciondelaanemiadelprematuro AT aguayotines usoprecozdelaeritropoyetinaenlaprevenciondelaanemiadelprematuro AT standenhjane usoprecozdelaeritropoyetinaenlaprevenciondelaanemiadelprematuro AT sanchezglina usoprecozdelaeritropoyetinaenlaprevenciondelaanemiadelprematuro AT cabellomangela usoprecozdelaeritropoyetinaenlaprevenciondelaanemiadelprematuro
_version_	1718435947619549184

Uso precoz de la eritropoyetina en la prevención de la anemia del prematuro

Ejemplares similares